Premium
A totally recombinant fibrin matrix for mesenchymal stem cell culture and delivery
Author(s) -
Wang Ou,
Ismail Ayman,
Fabian Frank Marco,
Lin Haishuang,
Li Qiang,
Elowsky Christian,
Carlson Mark A.,
Burgess Wilson,
Velander William H.,
Kidambi Srivatsan,
Lei Yuguo
Publication year - 2018
Publication title -
journal of biomedical materials research part a
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.849
H-Index - 150
eISSN - 1552-4965
pISSN - 1549-3296
DOI - 10.1002/jbm.a.36508
Subject(s) - fibrin , mesenchymal stem cell , recombinant dna , fibrinogen , tissue engineering , matrix (chemical analysis) , thrombin , materials science , extracellular matrix , biomedical engineering , cell culture , immunology , microbiology and biotechnology , biology , medicine , biochemistry , platelet , composite material , gene , genetics
Mesenchymal stem cells (MSCs) have been widely studied for tissue engineering and treating diseases in laboratories, clinical trials, and clinics. Fibrin matrices are often used to culture MSCs or increase the retention of MSCs at the injection site. However, fibrins made with the human plasma derived fibrinogen have high cost and risk of human pathogen transmission. In this article, we studied if fibrin matrices made with recombinant human fibrinogen, recombinant human thrombin, and recombinant human factor XIII could be used to culture and deliver MSCs. We systematically investigated the relationships between the fibrin matrix formulation, its nanostructure, and the behaviors of the cells in the matrix including the cell morphology, viability, and growth. We found that the fibrinogen concentration significantly affected the matrix structure and cell behaviors. We then used an optimized fibrin matrix to deliver human MSCs into mice subcutaneously. We found that the matrix could significantly enhance the retention of MSCs at the injection site. To our best knowledge, this is the first study on using fibrin matrices made with entirely recombinant proteins for culturing and delivering MSCs. © 2018 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 106A: 3135–3142, 2018.